Table 2.
Placebo (n=74) |
Rifaximin (n=77) |
Risk difference (95% CI, p values) |
|
Main analysis: available case | |||
Primary outcome data available | 61 | 69 | |
No recurrence | 43 (70.5%) | 58 (84.1%) | |
Recurrence | 18 (29.5%) | 11 (15.9%) | −13.7% (−28.1% to 0.7%, p=0.06) |
Number of participants with primary outcome data available is used as the denominator for CDI recurrence.
Risk difference/risk ratio and 95% CIs calculated using generalised estimating equations (with an exchangeable correlation matrix to account for hospital) using the Binomial family.
CDI, Clostridium difficile infection.